Investing.com -- AbbVie (NYSE:ABBV) has lifted his full-year income forecast, as the pharmaceutical group said its was seeing "momentum" in its operations after third-quarter net revenue topped ...

Michael, chief executive officer, AbbVie. "Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological and psychiatric conditions.

Richard Gonzalez listed T-cell engagers as a modality in which AbbVie had a high level of interest before he stepped down as CEO of the company. Responding to an analyst question about AbbVie’s ...

Michael, chief executive officer, AbbVie. Skyrizi and Rinvoq revenues were up 50.8% Y/Y to $3.2B and 45.3% to $1.6B, respectively, during the quarter, as the immunology portfolio generated over $ ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

The CEO of Hungarian pharmaceutical company Richter ... data that could decide whether the equity rally can sustain itself. AbbVie shares fell over 12% on Monday after an experimental ...

Skyrizi holds biologic share leadership in approximately 30 countries and boasts a “best-in-class profile” that presents a “very high bar” for rivals, AbbVie's chief commercial officer ...

To battle those disruptions, AbbVie, maker of three migraine treatment options, launched a contest this year to provide support for people whose migraines create obstacles in reaching their ...